Recombinant Gorilla C5AR1 is produced using heterologous expression systems, with validated specifications:
Specificity: Reactivity confirmed via SDS-PAGE and Western blot using anti-His monoclonal antibodies
Activity: Binds C5a with Kd values comparable to human C5AR1 (low nM range)
Cross-reactivity: Recognized by antibodies raised against human C5AR1 due to high sequence homology
Sepsis: C5AR1 blockade in murine models reduced mortality by enhancing pathogen clearance and preserving liver function .
COVID-19: Elevated C5a-C5AR1 signaling correlates with severe lung inflammation; recombinant proteins aid in studying alveolar injury mechanisms .
Cardiac Regeneration: C5AR1 inhibition attenuates cardiomyocyte proliferation post-injury in zebrafish, axolotl, and neonatal mouse models .
Recombinant Gorilla C5AR1 is used to screen inhibitors like:
| Drug | Phase | Target Disease |
|---|---|---|
| Avacopan | Approved | ANCA-associated vasculitis |
| PMX-53 | Phase 2 | Atopic dermatitis |
| PMX205 | Preclinical | Neurodegenerative disorders |
Immunogenicity: Non-human primate-derived proteins may trigger immune responses in humanized models .
Functional variability: Post-translational modifications differ across expression systems, affecting ligand affinity .
Therapeutic potential: Ongoing trials explore C5AR1 antagonists for cancer immunotherapy and COVID-19-related acute lung injury .
KEGG: ggo:101126529
STRING: 9593.ENSGGOP00000008426